SI1524971T1 - Izboljsan transdermalni sistem oddajanja - Google Patents

Izboljsan transdermalni sistem oddajanja

Info

Publication number
SI1524971T1
SI1524971T1 SI200330559T SI200330559T SI1524971T1 SI 1524971 T1 SI1524971 T1 SI 1524971T1 SI 200330559 T SI200330559 T SI 200330559T SI 200330559 T SI200330559 T SI 200330559T SI 1524971 T1 SI1524971 T1 SI 1524971T1
Authority
SI
Slovenia
Prior art keywords
functional drug
amine functional
matrix
drug
tds
Prior art date
Application number
SI200330559T
Other languages
English (en)
Inventor
Mike Hannay
Dietrich Wilhelm Schacht
Hans-Michael Wolff
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of SI1524971T1 publication Critical patent/SI1524971T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200330559T 2002-07-30 2003-07-28 Izboljsan transdermalni sistem oddajanja SI1524971T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02016864A EP1386604A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system
EP03766330A EP1524971B1 (en) 2002-07-30 2003-07-28 Improved transdermal delivery system
PCT/EP2003/008319 WO2004012719A1 (en) 2002-07-30 2003-07-28 Improved transdermal delivery system

Publications (1)

Publication Number Publication Date
SI1524971T1 true SI1524971T1 (sl) 2007-02-28

Family

ID=30011092

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200330559T SI1524971T1 (sl) 2002-07-30 2003-07-28 Izboljsan transdermalni sistem oddajanja

Country Status (22)

Country Link
EP (2) EP1386604A1 (sl)
JP (1) JP4837915B2 (sl)
KR (1) KR101016914B1 (sl)
CN (1) CN100558350C (sl)
AT (1) ATE343380T1 (sl)
AU (1) AU2003266252B2 (sl)
BR (1) BR0313092A (sl)
CA (1) CA2490573C (sl)
CY (1) CY1105878T1 (sl)
DE (1) DE60309329T2 (sl)
DK (1) DK1524971T3 (sl)
ES (1) ES2273042T3 (sl)
HK (1) HK1083458A1 (sl)
IL (1) IL165917A (sl)
MX (1) MXPA05000349A (sl)
NO (1) NO334187B1 (sl)
NZ (1) NZ537476A (sl)
PL (1) PL376999A1 (sl)
PT (1) PT1524971E (sl)
SI (1) SI1524971T1 (sl)
WO (1) WO2004012719A1 (sl)
ZA (1) ZA200500255B (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
JP5546013B2 (ja) * 2008-02-27 2014-07-09 久光製薬株式会社 貼付剤及び包装体
ES2536206T3 (es) * 2008-02-27 2015-05-21 Hisamitsu Pharmaceutical Co., Inc. Parche medicinal
ES2679800T3 (es) * 2009-12-22 2018-08-31 Lts Lohmann Therapie-Systeme Ag Polivinilpirrolidona para la estabilización de una dispersión sólida de la forma no cristalina de rotigotina
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
ES2694662T3 (es) 2013-07-03 2018-12-26 Lts Lohmann Therapie-Systeme Ag Sistema terapéutico transdérmico con componente electrónico
EP4238580A3 (en) 2014-05-20 2023-10-25 LTS Lohmann Therapie-Systeme AG Transdermal delivery system including an interface mediator
CA2948220C (en) 2014-05-20 2023-06-20 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
CA2948219C (en) 2014-05-20 2023-04-04 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
FI3854388T3 (fi) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermaalinen hoitojärjestelmä, jossa on vaikuttava aine rotigotiini ja ainakin yksi ei-amiiniresistentti silikoniliima
EP3949956A1 (en) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
IT1311696B1 (it) * 1999-06-22 2002-03-19 Zanussi Elettromecc Compressore del fluido frigorigeno azionato da un motore elettricoa frequenza di alimentazione variabile
JP2002045699A (ja) * 2000-08-08 2002-02-12 Mitsubishi Electric Corp 排ガス浄化用層状電気化学触媒
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
ATE364380T1 (de) * 2001-03-16 2007-07-15 Alza Corp Transdermales pflaster zur verabreichung von fentanyl
EP1372614A4 (en) * 2001-03-16 2007-10-31 Andrx Pharmaceuticals Llc SULPHONYL UREA FORMULATION WITH CONTROLLED RELEASE
DK1256340T3 (da) * 2001-05-08 2003-12-01 Sanol Arznei Schwarz Gmbh Forbedret transdermalt, terapeutisk system til behandlingen af Parkinsons sygdom
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine

Also Published As

Publication number Publication date
IL165917A (en) 2007-07-24
ZA200500255B (en) 2006-01-25
NO20050770L (no) 2005-02-11
DE60309329T2 (de) 2008-04-17
HK1083458A1 (en) 2006-07-07
EP1386604A1 (en) 2004-02-04
MXPA05000349A (es) 2005-03-31
WO2004012719A1 (en) 2004-02-12
AU2003266252B2 (en) 2008-11-20
PT1524971E (pt) 2007-01-31
EP1524971A1 (en) 2005-04-27
KR101016914B1 (ko) 2011-02-22
BR0313092A (pt) 2005-06-21
KR20050025638A (ko) 2005-03-14
PL376999A1 (pl) 2006-01-23
DE60309329D1 (de) 2006-12-07
IL165917A0 (en) 2006-01-15
CY1105878T1 (el) 2011-02-02
AU2003266252A1 (en) 2004-02-23
ES2273042T3 (es) 2007-05-01
CN1671365A (zh) 2005-09-21
JP2005535686A (ja) 2005-11-24
CN100558350C (zh) 2009-11-11
NZ537476A (en) 2007-08-31
JP4837915B2 (ja) 2011-12-14
ATE343380T1 (de) 2006-11-15
EP1524971B1 (en) 2006-10-25
DK1524971T3 (da) 2007-02-19
CA2490573C (en) 2011-06-07
NO334187B1 (no) 2014-01-13
CA2490573A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
HK1083458A1 (en) Improved transdermal delivery system
NO20050472L (no) Forbedret transdermalt leveringssystem for administrering av rotigotin
MXPA04001676A (es) Sistema terapeutico transdermico con fentanilo o sustancias relacionadas.
MY105347A (en) Transdermal therapeutic system comprising as active component buprenorphine
NO20001003L (no) Transdermalt terapeutisk system omfattende et trykksensitivt adhesivt reservoarsjikt og et unidireksjonalt elastisk dekksjikt
WO2001068060A3 (de) Stabilisierte übersättigte transdermale therapeutische matrixsysteme
DK1143938T3 (da) Transdermalt terapeutisk system med en selvklæbende matrix, der indeholder organiske syreadditionssalte af alkaloider af morphin- eller morphin-type
MY110391A (en) Nitroglycerin-containing patch, a process for the production and the use thereof
DE50100870D1 (de) Transdermales therapeutisches system zur verabreichung von zaleplon
PL339226A1 (en) Transdermal therapeutic system containing scopolamine in the form of base as its active substance
DE20221161U1 (de) Transdermales therapeutisches System mit Fentanyl bzw. verwandten Substanzen